Biocon Issues Rs 200 Crore Commercial Papers At 6.80%

Biocon Limited, India’s leading biopharmaceutical company, announced the issuance of commercial papers (CP) amounting to Rs 200 crore on January 2, 2026. The move is part of its short-term funding strategy, aimed at strengthening liquidity and supporting operational requirements.

Key Highlights

• Issue size stands at Rs 200 crore through private placement.
• Tenure of the instrument is 60 days, maturing on March 3, 2026.
• Coupon rate offered is 6.80%, payable on maturity.
• The CPs are proposed to be listed on the National Stock Exchange of India.
• Credit rating for the issue is IND A1+, reflecting strong creditworthiness.
• Issued in favor of Kotak Mahindra Trustee Company Ltd A/C Kotak Low Duration Fund and Kotak Floating Rate Fund.
• No security or charge has been created over assets for this issuance.
• Allotment date was January 2, 2026, with repayment scheduled on March 3, 2026.

Conclusion
The issuance underscores Biocon’s prudent financial management and reliance on short-term instruments to optimize liquidity. With strong credit ratings and institutional backing, the company continues to reinforce its financial resilience while pursuing growth in the biopharma sector.

Sources: Company Filing (BSE, NSE), Biocon Official Disclosure